The anticoagulant treatment of coronary disease in general and myocardial infarction in particular has received world-wide appraisal following its inception 25 years ago. After an initially enthusiastic reception it began to lose favour. In the light of recent publications it appears appropriate to consider further a previously reported series of cases that has now been followed up for a further three years.
SUBJECTS AND METHODS
A series of 461 cases of coronary disease, treated with anticoagulants, was reported in 1966 (Royston, 1966 , 1967 . The cases were drawn from a typically suburban dormitory area with a small industrial population and treated under the National Health Service. The cases were divided into two groups: those with myocardial infarction with or without previous angina, and those with angina without any history to suTggest a previous frank myocardial infarct. The myocardial infarction cases were subdivided into the age-groups of under 55 years and 55 years and over. Deaths in hospital, anticoagulant treatment for less than 1 month, a history of peptic ulcer, gross obesity, and a blood pressure over 110 mm. Hg diastolic led to exclusion.
All patients were traced successfully, and, when alive and unable to attend for a personal interview, they were considered as withdrawals at the time of their last attendance reported in the case papers.
Details of deaths were obtained from hospital records, general practitioners, coroners' officers, and post-mortem records.
The survivors from the original series have been followed up for a further 550 treatment years to a total of 1700 treatment years. The duration of treatment is illustrated in Fig. 1 and the age distribution at the onset of treatment in Fig. 2 . Treatment was stopped in 31 patients: 8 for haemorrhage (2 with underlying pathological lesions), 14 for neoplasms, operations, or irregular attendance, and 9 for change of domicile. They were all treated as withdrawals from the trial on stopping anticoagulant treatment.
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The calculation of results included all patients admitted to the trial whether withdrawn or not. Where anticoagulant treatment was stopped for a condition from which death followed or death occurred within ., (Table II) .
In terms of man months the mortality is 0'25/100 man months compared with the earlier figure of 033/100 man months (Royston, 1967) .
Angina. The 108 cases of angina of all ages without any history of myocardial infarction have a 3-and 5-year survival rate of 93 and 83 per cent, respectively, and 72 per cent at 7 years (Table III Lovell et al. (1967) have recorded a survival rate for men of all ages on anticoagulant treatment of about 90 per cent at 1 year, 85 per cent at 2 years, and 75 per cent at 3 years, though the latter figure related to a small number of cases. In the present series, the survival rate at one year is 96 per cent and at 2 years 95 per cent, and falls from 91-5 to 82 per cent over the three-five-year period, the number of cases observed being 160 at 5 years. These figures endorse Lovell's findings, and owing to the greater number treated at 3 years, are more significant at that level.
Lovell felt that anticoagulant treatment improved the prognosis only in his patients aged 55 years and under. Table II and Fig. 3 show tliat, in the present series, though the younger age-group does better than the older, the benefit is not confined to it, nor is the benefit only confined to the first two years of treatment. In another controlled trial (Report of the U.S. Veterans Administration, 1965) there were 476 men, aged 55 and under: in the group on anticoagulants the survival rates at two years and three years were 94 and 90 per cent, compared with 97 and 86-5 per cent for this series.
In 1965 in the M.R.C. low fat trial (A Research Committee, 1965) 252 men with recent myocardial infarction under the age of 60 and without a previous infarct were treated without long-term anticoagulants. They were drawn from a similar population to the present series, were treated in similar hospitals, and the same criteria for diagnosis were used. They therefore form a reasonable control group, though not a perfect one. Any bias is against the present series which contains over 30 per cent ofmen aged over 59, a proportion of second infarcts and associated medical conditions, all those that would have been excluded from the M.R.C. trial. The M.R.C. reported survival at 3 years and 5 years of 84-7 and 77 2 per cent compared with 91 5 and 82 per cent (Fig. 5) . The present series is significantly better at both intervals: p= <0 01 and < 0 0005, respectively. C. F. Borchgrevink (World Med., 1967) , speaking at the Lauder Brunton Centenary Symposium in Edinburgh last year, reported a 5-year survival of 93 per cent in angina on anticoagulant treatment against a control figure of 70 per cent. These are the best figures reported so far. He contends that anticoagulant treatment is of value in angina. The present results support this view, being significantly better than his control figures.
Considering all cases of coronary disease with or without infarction, a comparison between the outlook for angina alone and those with infarcts shows great similarity, provided they are both receiving anticoagulant treatment (Fig. 4) . The infarction group represents the survivors after admission to hospital, and can be expected already to have suffered about a 20 per cent mortality in hospital.
Even a special coronary unit has recently had a mortality of 17-5 per cent (Lawrie et al., 1967 Anticoagulant therapy is the long-term treatment ed. It seems that in hospital cases, provided of choice in men with coronary heart disease, whery occurs from the initial infarct, and long-ther manifested by angina alone or-by frank myorytocagursnt treatment is given, the episode cardial infarction. Such treatment should be connticoagulant treatment is given, te episode tinued for at least 5 years and probably longer.
arction has surprisingly little effect on the Further study is required to determine its optimum Xrm prognosis, as compared with coronary d
It therefore seems wise to instigate anticoagulant treatment as soon as the diagnosis of angina is made rather than wait for infarction to occur with its additional mortality in hospital.
Further study is required to determine the optimum period of treatment and the age limit above which anticoagulant treatment would not normally be started. Consideration must also be given as to whether anticoagulant treatment already begun
